FDA approves oliceridine (Olinvyk), an opioid agonist for management of moderate to severe acute pain in adults

Oliceridine is indicated for short-term intravenous use in hospitals or other controlled clinical settings. Approval is based on clinical trial data in 1,535 patients which demonstrated similar safety to opioids, and efficacy vs placebo with a max daily dose limit of 27mg.